Print this page for your doctor
CLINICAL TRIAL SUMMARY
MDACC Study No:
(clinicaltrials.gov NCT No:
A Phase 2, Open-Label Study Evaluating the Efficacy, Safety, Tolerability, and Pharmacodynamics of GS-9973 in Combination with Idelalisib in Subjects with Relapsed or Refractory Hematologic Malignancies
The initial goal of this clinical research study was to learn if GS-9973 in
combination with idelalisib can help to control CLL. The safety of these drugs
was also studied.
Due to a serious safety concern of inflammation of the lungs, this combination
treatment has been stopped. The increased risk of lung problems has not been
seen with GS-9973 alone.
If you and your Study Doctor have decided that you should continue in the study
you will be receiving only GS-9973.
Phase of Study:
Both at MDACC & and Other Sites
Estimated Length of Stay in Houston:
Gilead Sciences, Inc.
Study Contact Information
For Clinical Trial Enrollment:
For General Questions about Clinical Trials:
Study Objectives / Outcomes
Study Status Information
Resources and Links
Return to List